NCT03674814View on ClinicalTrials.gov

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 23, 2018

Primary Completion Date

January 10, 2026

Study Completion Date

March 10, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Enzalutamide

Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).

DRUG

Relacorilant

Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.

Trial Locations (1)

60637

University Of Chicago Medicine Comprehensive Cancer Center, Chicago

Sponsors

Collaborators (1)

Corcept Therapeutics
All Listed Sponsors
collaborator

Corcept Therapeutics

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER